… In the phase II portion of this study, 162 patients with BRAFV600 mutated advanced melanoma
with no prior BRAF targeted therapy were assigned 1:1:1 to receive combination therapy …

… therapies with more precise molecular targets, the challenge of using combination therapies
… in which cases the use of the combination of the latest therapies for psoriasis may be useful. …

… We analyzed data on ezetimibe–statin combination therapy in terms of hypolipemic efficacy,
… We analyzed the ezetimibe–statin combination therapy in terms of hypolipemic efficacy, …

… The results of the first phase III trials of combination therapy should be available in late
2013 (COMBI-V). At present, little is known regarding mechanisms of resistance to combined …

… which technique combinations are best for specific tumours. This review article summarizes
the latest scientific evidence highlighting the future prospective of this winning combination, …

… combination therapy was also seen in patients who had received more than one prior line of
therapy… the PFI by using a nonplatinum combination therapy. Patients with ‘partially platinum…

… September 18, 2019 during the 55th Annual Meeting of the European Association for the
Study of Diabetes (EASD) in Barcelona Spain, this review discusses the initial evidence that …

… Interim results of an ongoing prospective multicenter single arm phase II study of dabrafenib
monotherapy, or combination therapy with trametinib in patients with BRAF V600E-mutated …

… In conclusion, non-platinum combination therapy has not been shown to be superior to … is
to offer to our patients all potential combinations of therapies that we have, in order to reduce …

… therapies for CRPC, the agents currently in late-phase clinical trials, and notable early-phase
trials of novel therapies and their combinations, … or may not benefit from specific therapies. …